Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Genmab A/S < Previous 1 2 Next > TEPKINLY® (epcoritamab) Receives Second European Commission Approval for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma August 19, 2024 From Genmab A/S Via Business Wire Tickers GMAB TEPKINLY® (epcoritamab) Receives Second European Commission Approval for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma August 19, 2024 From Genmab A/S Via GlobeNewswire Genmab Announces Changes to its Executive Committee August 16, 2024 From Genmab A/S Via Business Wire Tickers GMAB Genmab Announces Financial Results for the First Half of 2024 August 08, 2024 From Genmab A/S Via GlobeNewswire Genmab Updates 2024 Financial Guidance August 08, 2024 From Genmab A/S Via GlobeNewswire Genmab Takes Full Control of Acasunlimab Development Program August 05, 2024 From Genmab A/S Via GlobeNewswire Epcoritamab (TEPKINLY®) Receives Positive CHMP Opinion for the Treatment of Adults with Relapsed/ Refractory Follicular Lymphoma June 28, 2024 From Genmab A/S Via Business Wire Tickers GMAB Epcoritamab (TEPKINLY®) Receives Positive CHMP Opinion for the Treatment of Adults with Relapsed/ Refractory Follicular Lymphoma June 28, 2024 From Genmab A/S Via GlobeNewswire EPKINLY® (epcoritamab-bysp) Approved by U.S. FDA for Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL) June 26, 2024 From Genmab A/S Via Business Wire Tickers GMAB Investigational Tisotumab Vedotin Phase 2 Data Demonstrates Encouraging Antitumor Activity in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) June 03, 2024 From Genmab A/S Via Business Wire Tickers GMAB Preliminary Analysis of Data Evaluating Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Demonstrates 95% Overall Response Rate in Patients with Previously Untreated Follicular Lymphoma June 02, 2024 From Genmab A/S Via Business Wire Tickers GMAB Genmab to Showcase Data in Various Patient Populations to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting May 23, 2024 From Genmab A/S Via Business Wire Tickers GMAB Genmab Completes Acquisition of ProfoundBio May 21, 2024 From Genmab A/S Via Business Wire Tickers GMAB Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC) June 01, 2024 From Genmab A/S Via Business Wire Tickers BNTX GMAB Genmab Completes Acquisition of ProfoundBio May 21, 2024 From Genmab A/S Via GlobeNewswire Genmab to Present New and Updated Results From Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies at the 2024 European Hematology Association (EHA) Congress May 14, 2024 From Genmab A/S Via Business Wire Tickers GMAB Genmab Announces Financial Results for the First Quarter of 2024 May 02, 2024 From Genmab A/S Via GlobeNewswire TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer April 29, 2024 From Genmab A/S Via Business Wire Tickers GMAB PFE TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer April 29, 2024 From Genmab A/S Via GlobeNewswire Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio April 03, 2024 From Genmab A/S Via Business Wire Tickers GMAB Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio April 03, 2024 From Genmab A/S Via GlobeNewswire U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Epcoritamab (EPKINLY®) for Difficult-to-Treat Relapsed or Refractory Follicular Lymphoma February 27, 2024 From Genmab A/S Via Business Wire Tickers GMAB Genmab Announces Initiation of Share Buy-Back Program February 14, 2024 From Genmab A/S Via GlobeNewswire Genmab Publishes 2023 Annual Report February 14, 2024 From Genmab A/S Via GlobeNewswire Tisotumab Vedotin Marketing Authorization Application Validated by European Medicines Agency for Treatment of Recurrent or Metastatic Cervical Cancer February 02, 2024 From Genmab A/S Via Business Wire Tickers GMAB PFE TIVDAK® (tisotumab vedotin-tftv) Supplemental Biologics License Application Accepted for Priority Review by U.S. Food and Drug Administration for Patients with Recurrent or Metastatic Cervical Cancer January 09, 2024 From Genmab A/S Via Business Wire Tickers GMAB PFE New Pivotal Data for Bispecific Antibody Epcoritamab (DuoBody® CD3xCD20) Demonstrates High Overall and Complete Responses in Patients with Hard-To-Treat Relapsed/Refractory Follicular Lymphoma (FL) December 09, 2023 From Genmab A/S Via Business Wire Tickers GMAB Genmab Announces Positive Regulatory Updates for Epcoritamab (EPKINLY®/TEPKINLY®) for the Treatment of Relapsed/Refractory Follicular Lymphoma November 27, 2023 From Genmab A/S Via Business Wire Tickers GMAB Major Shareholder Announcement November 09, 2023 From Genmab A/S Via GlobeNewswire Major Shareholder Announcement November 08, 2023 From Genmab A/S Via GlobeNewswire < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.